Search results
Results from the WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
It was developed by Sanofi. The most common side effect is hypoglycemia (low blood glucose levels). [51] Insulin glulisine was approved for medical use in the United States [49] [52] and the European Union in 2004. [51] It is currently patented by Sanofi, and is therefore only produced by said company under the brand name Apidra. [53]
Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug (), [8] used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis.
Sanofi plans to advance blood cancer drugs known as anti-CD38, which include Sarclisa, despite GenMab and Johnson & Johnson's strong foothold with Darzalex in the same class.
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of ...
On March 9, 2010, Sanofi-Aventis announced [6] it had exercised an option to combine Merial with Intervet/Schering Plough, the animal health business of Merck. The new joint venture would be equally owned by Merck and Sanofi-Aventis. On March 22, 2011, they announced the mutual termination of their agreement to form a new animal health joint ...
Across the channel, Paris-based Sanofi-Aventis announced today it agreed to develop blood-sugar monitoring systems with AgaMatrix, a privately held U.S. company. The pair will codevelop diabetes ...
Hoechst AG (German pronunciation: [ˈhøːçst]) was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group.